Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.
暂无分享,去创建一个
P. Gaulard | B. Coiffier | J. Diebold | R. Bouabdallah | C. Meijer | C. Gisselbrecht | A. Feller | N. Mounier | C. Haioun | J. Emile | A. Delmer | E. Raffoux | J. Brière | A. Bosly | N. Mourad | J. Emile | Jean-François Emile
[1] Prof. Dr. med. Alfred Christian Feller,et al. Histopathology of Nodal and Extranodal Non-Hodgkin’s Lymphomas , 2012, Springer Berlin Heidelberg.
[2] N. Schmitz,et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] G. Salles,et al. Angioimmunoblastic T-Cell Lymphoma: Clinical and Laboratory Features at Diagnosis in 77 Patients , 2007, Medicine.
[4] P. Gaulard,et al. Histologic Evolution of Angioimmunoblastic T-cell Lymphoma in Consecutive Biopsies: Clinical Correlation and Insights Into Natural History and Disease Progression , 2007, The American journal of surgical pathology.
[5] Christian Gisselbrecht,et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. , 2007, Blood.
[6] T. Molina,et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] T. Molina,et al. Angioimmunoblastic T-Cell Lymphoma: A Clinicopathologic Study of 158 Patients Treated in GELA (Groupe d’ Etude des Lymphomes de l’ Adulte) Trials. , 2006 .
[8] P. Schaerli,et al. Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells. , 2006, Blood.
[9] A. Dogan,et al. Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified , 2006, Modern Pathology.
[10] S. Pileri,et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Copie-Bergman,et al. Expression of CXCL13 by Neoplastic Cells in Angioimmunoblastic T-Cell Lymphoma (AITL): A New Diagnostic Marker Providing Evidence That AITL Derives From Follicular Helper T Cells , 2006, The American journal of surgical pathology.
[12] C. Mackay,et al. Follicular B helper T cells in antibody responses and autoimmunity , 2005, Nature Reviews Immunology.
[13] A. Attygalle,et al. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? , 2005, Blood.
[14] N. Schmitz,et al. The International Prognostic Index determines the outcome of patients with nodal mature T‐cell lymphomas , 2005, British journal of haematology.
[15] T. Molina,et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.
[16] A. Stamatoullas,et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] E. Butcher,et al. Unique gene expression program of human germinal center T helper cells. , 2004, Blood.
[18] E. Iannitto,et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.
[19] T. Molina,et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. , 2003, Blood.
[20] A. Dogan,et al. Angioimmunoblastic T‐cell lymphoma , 2003, British journal of haematology.
[21] P. Gaulard,et al. Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein–Barr virus infection. A different subtype of AILD-TL? , 2002, Leukemia.
[22] T. Molina,et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. Hossfeld. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .
[24] B. Nathwani,et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] P. Isaacson,et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. , 2002, Blood.
[26] P. Vyas,et al. Pathology and genetics: Tumours of haematopoietic and lymphoid tissues , 2001 .
[27] P. Gaulard,et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Jason G. Cyster,et al. A chemokine-driven positive feedback loop organizes lymphoid follicles , 2000, Nature.
[29] B. Coiffier,et al. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] T. Molina,et al. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. , 1999, Leukemia & lymphoma.
[32] A. López-Guillermo,et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] P. Gaulard,et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.
[34] Y. Ko,et al. Angioimmunoblastic lymphoma (AILD-type T-cell lymphoma) with hyperplastic germinal centers. , 1998, The American journal of surgical pathology.
[35] K. Matsue,et al. Development of Epstein-Barr virus-associated B cell lymphoma after intensive treatment of patients with angioimmunoblastic lymphadenopathy with dysproteinemia. , 1998, International journal of hematology.
[36] J. Blay,et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] R. Warnke,et al. Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] B. Nathwani,et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .
[39] Y. C. Chen,et al. Angioimmunoblastic lymphadenopathy with dysproteinemia--lack of a prognostic value of clear cell morphology. , 1997, Oncology.
[40] O. Olopade,et al. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine [letter] , 1996 .
[41] M. Engelhard,et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[43] E. Jaffe,et al. B-cell lymphoma after angioimmunoblastic lymphadenopathy: a case with oligoclonal gene rearrangements associated with Epstein-Barr virus. , 1993, Blood.
[44] E. Jaffe,et al. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. , 1992, Blood.
[45] D. Huhn,et al. Recombinant human interferon-alpha in the treatment of angioimmunoblastic lymphadenopathy: results in 12 patients. , 1991, Leukemia.
[46] B. Coiffier,et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] K. Aozasa,et al. Angioimmunoblastic lymphadenopathy. Review of 44 patients with emphasis on prognostic behavior , 1989, Cancer.
[48] K. Lennert,et al. Updated Kiel classification for lymphomas , 1989, The Journal of pathology.
[49] Y. Kagami,et al. Clinicopathologic, immunophenotypic, and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma. , 1988, Blood.
[50] B. Coiffier,et al. Prognostic factors in angioimmunoblastic lymphadenopathy , 1987, Cancer.
[51] B. Nathwani,et al. Angioimmunoblastic lymphadenopathy long‐term follow‐up study , 1983, Cancer.
[52] A. Saxon,et al. Angioimmunoblastic lymphadenopathy with dysproteinemia: A Pathogenetic link between physiologic lymphoid proliferation and malignant lymphoma☆ , 1979 .
[53] G. Iordăchescu,et al. [Angioimmunoblastic lymphadenopathy with dysproteinemia]. , 1979, Revista de medicina interna, neurologe, psihiatrie, neurochirurgie, dermato-venerologie. Medicina interna.
[54] 山川 敬子,et al. Angio-Immunoblastic Lymphadenopathy with Dysproteinemia , 1979 .
[55] B. Nathwani,et al. Malignant lymphoma arising in angio‐immunoblastic lymphadenopathy , 1978, Cancer.
[56] R. Lukes,et al. Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease. , 1975, The New England journal of medicine.
[57] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[58] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[59] H. Müller-Hermelink,et al. Angioimmunoblastic T cell lymphoma is derived from mature T‐helper cells with varying expression and loss of detectable CD4 , 2003, International journal of cancer.
[60] E. Kimby,et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. , 2003, Haematologica.
[61] E. Iannitto,et al. Response to low-dose oral methotrexate and prednisone in two patients with angio-immunoblastic lymphadenopathy-type T-cell lymphoma. , 2001, The hematology journal : the official journal of the European Haematology Association.
[62] P. Gaulard,et al. Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma. , 2001, The hematology journal : the official journal of the European Haematology Association.
[63] James Olen Armitage,et al. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.
[64] O. Olopade,et al. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. , 1996, Blood.